The call on whether to let Brazil's pharma company União Química produce Sputnik V, as planned, is pending. The company's president is furious with Anvisa's requests for more data, calling it "hair in the egg" -- looking for the slightest justification not to do something. (2/12)
Anvisa was reportedly denied access to the Gamaleya Institute -- where Sputnik V was developed, and where quality control is carried out -- several times during its inspection visit to Moscow. The Anvisa spokesperson described the situation as "frustrating." (4/12)
Second -- and I'm burying the lede here -- in *all* the Sputnik V batches sent to Brazil for lab testing, the adenoviruses used in the vaccine, which are supposed to be modified so that they can't replicate after entering human cells, were able to replicate. (5/12)
We don't know how this might affect the health of someone who's received the vaccine. Anvisa says, "the correct strategy would be to develop a study on the potential impact of this." But there is no indication that Gamaleya has done so. (6/12)
Third, Anvisa was unable to validate the methodology Russian studies used to measure the immune system response generated by Sputnik V. There were also issues with the criteria and processes Gamaleya used to track and describe adverse events following vaccination. (7/12)
Fourth, there were questions about the quality of Sputnik V's efficacy data (reported at 91.6% in the Lancet), stemming from uncertainties about the study protocols that were in place: collection of samples, monitoring of symptoms, other issues. (8/12)
Finally, quality control. At a factory visit in Russia, Anvisa detected problems that could affect the sterility of the vaccine. There isn't adequate guarantee that the Sputnik V leaving manufacturing facilities is the same Sputnik V that was produced in Gamaleya's labs. (9/12)
You can follow @jtwigg9.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: